STADA Arzneimittel AG Company Profile
STADA - Generics with “value for money”
Generics contributed 73.2% to sales in 2006 (previous year: 74.3%) and represents STADA’s largest core segment by far. In 2006, sales in the generics core segment rose by 20% to EUR 911.2 million (2005: EUR 759.3 million1)). A part of this growth is based on the acquisition of the Serbian Hemofarm, whose product portfolio includes approx. 75% of generics. Group sales in the generics core segment rose by 32% to EUR 821.5 million in the first nine months of 2007 (1-9/2006: EUR 624.7 million2)).
Generics are drugs which, after expiration of the patent or other relevant commercial property rights, are offered in the same quality but for lower prices than products of an initial supplier having the same active ingredient. This means generics are typical “multisource products” with active ingredients that any supplier can readily procure.
Generics have a high structural growth potential. The basis for this on the one hand is the pressure to contain costs in numerous national health care markets because generics allow, in many indication areas, a low-cost medical therapy without quality cutbacks. On the other hand, the continuous expiration of patents or other commercial property rights ensures a constant automatic expansion of market potential available for generic competition. Historical data as well as forecast market data demonstrate the growth momentum of generics which is characterized by these two sustainable market trends.
There is no question that spending restraints in the different national health care systems form the basis for the long-term growth potential of generics suppliers. However, due to the associated low price expectations, the generics market is a very price-sensitive segment. Reactions to lasting or temporary challenges occurring in individual national markets due to regulation and /or competition must be specifically and flexibly targeted at the individual national market.
In Germany, the Group's generic drugs are marketed by the Group subsidiary STADApharm GmbH, STADA Medical GmbH, ALIUD Pharma GmbH & Co. KG, cell pharm GmbH and Hemofarm GmbH3).
STADA´s sales network outside of Germany consists the following sales companies in Europe: Austria, Belgium, Bosnia, the Czech Republic, Denmark, Finland, France, Ireland, Italy, Lithuania, Macedonia, Montenegro, the Netherlands, Portugal, Romania, Russia, Serbia, Spain, Sweden, Ukraine and United Kingdom.
Further own sales companies outside of Europe are in: China, Kazakhstan, Vietnam, Philippines and Thailand.
Location
5 Cedar Brook Drive
Bad Vilbel
D-61118
Germany
Contact
Phone: +49 6101 603-0
Fax: +49 6101 603-259
Email: info@stada.de
News Articles
DGAP-Stimmrechte: STADA Arzneimittel AG (deutsch)
STADA Arzneimittel AG: Veröffentlichung gemäß § 26 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung STADA Arzneimittel AG 23.05.2013 13:31 Veröffentlichung einer Stimmrechtsmitteilung, über...
DGAP-Gesamtstimmrechtsmitteilung: STADA Arzneimittel AG (deutsch)
STADA Arzneimittel AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 26a WpHG mit dem Ziel der europaweiten Verbreitung STADA Arzneimittel AG / Veröffentlichung der Gesamtzahl der Stimmre....
STADA Arzneimittel Prelim. FY12 Profit Rises, Increases Dividend
BAD VILBEL (dpa-AFX) - STADA Arzneimittel AG (STDAF.PK) Thursday reported an increase in preliminary earnings for the full-year and said, on the basis of the improved results, it is expected to in...
STADA Arzneimittel-Aktie: Ausblick unverändert
Hannover - Thorsten StrauĂź, Analyst der Nord LB, stuft die Aktie von STADA Arzneimittel (ISIN DE0007251803/ WKN 725180) nach wie vor mit "halten" ein.In den ersten neun Monaten habe der Konzern ein.....
STADA Arzneimittel Backs Positive Forecast; Dividend Proposal Unchanged
BAD VILBEL (dpa-AFX) - German pharmaceutical and healthcare company STADA Arzneimittel AG (STDAF.PK) on Thursday backed its positive outlook for fiscal 2013 and 2014, after it reported a profit th...
DGAP-HV: STADA Arzneimittel Aktiengesellschaft: -9-
DJ DGAP-HV: STADA Arzneimittel Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 05.06.2013 in Frankfurt am Main mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG ....
DGAP-HV: STADA Arzneimittel Aktiengesellschaft: -8-
DJ DGAP-HV: STADA Arzneimittel Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 05.06.2013 in Frankfurt am Main mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG ....
DGAP-HV: STADA Arzneimittel Aktiengesellschaft: -6-
DJ DGAP-HV: STADA Arzneimittel Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 05.06.2013 in Frankfurt am Main mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG ....
Drugs and Medications
Bekunis natures gentle stimulant laxative [roha arzneimittel GmbH]
Bekunis Nature's Gentle Stimulant Laxative Tablets
Bekunis natures gentle laxative herbal tea [roha arzneimittel GmbH]
Bekunis Nature's Gentle Laxative Herbal Tea
Bekunis natures gentle laxative instant tea [roha arzneimittel GmbH]
Bekunis Nature's Gentle Laxative Instant Tea
Ampicillin [DAVA Pharmaceuticals, Inc.]
AMPICILLIN CAPSULES, USP 250 mg and 500 mgAMPICILLIN FOR ORAL SUSPENSION, USP 125 mg/5 mL and 250 mg/5 mLRx Only
Penicillin v potassium [Rebel Distributors Corp]
Penicillin-VKPenicillin V Potassium Tablets, USP500 mg (800,000 Units)
PubMed Articles
The 4th amendment of the Medical Device Law introduced the authorization procedure for clinical trials with medical devices. The Federal Institute for Drugs and Medical Devices ("Bundesinstitut fĂĽr A...
Numerical study of oxygen transport in a carotid bifurcation.
This study investigates the oxygen mass transport in the region around the human carotid bifurcation, particularly addressing the effects of bifurcation geometry and pulsatile blood flow on the oxygen...
In Germany, the tissue law came into effect on 1 August 2007. The law implemented the requirements of EC directives on quality and safety of human tissues and cells in the German Transplantation Act...
Clinical Trials
None
Companies
STADA - Generics with “value for money” Generics contributed 73.2% to sales in 2006 (previous year: 74.3%) and represents STADA’s largest core segment by far. In 2006, sales in the generics cor...
Bundesinstitut fĂĽr Arzneimittel und Medizinprodukte
Das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) ist eine selbständige Bundesoberbehörde im Geschäftsbereich des Bundesministeriums für Gesundheit. Aufgrund des Gesetzes über die...
Nil
RIEMSER Arzneimittel AG is a medium-sized pharmaceutical company engaging in research and headquartered in the West Pomeranian town of Greifswald - Island of Riems. The stockholding company (AG) opera...
Boehringer Ingelheim Pharma GmbH & Co. KG
Boehringer Ingelheim erforscht, entwickelt, produziert und vermarktet Arzneimittel für Menschen in aller Welt.Mit 37.406 Mitarbeitern, die in 143 Gesellschaften auf allen Kontinenten beschäftigt sin...
More Information about "STADA Arzneimittel AG" on BioPortfolio
We have published hundreds of STADA Arzneimittel AG news stories on BioPortfolio along with dozens of STADA Arzneimittel AG Clinical Trials and PubMed Articles about STADA Arzneimittel AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of STADA Arzneimittel AG Companies in our database. You can also find out about relevant STADA Arzneimittel AG Drugs and Medications on this site too.
